Investors

Key press releases

13 Mar 2025
18:15 E.S.T.

Finance

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

07 Mar 2025
04:36 E.S.T.

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

24 Feb 2025
01:30 E.S.T.

Science

Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

Key upcoming events

14 Mar 2025

Cellectis Q4 & full year 2024 earnings call

Learn more

03 Apr 2025

The Van Lanschot Kempen Life Sciences Conference

Learn more

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$1.2400

-0.0500 (-3.8760%)

Prev. close: 1.2900
Volume: 13.939M
High: 1.4000
Capitalization: 89.396M

€1.2240

-0.0240 (-1.9231%)

Prev. close: 1.2480
Volume: 2.346M
High: 1.6900
Capitalization: 88.243M

See stock information

Covering research analysts

Barclays - Gena Wang

Bryan Garnier - Oscar Haffen-Lamm

Goldman Sachs - Salveen Richter

Jefferies - Kelly Shi

JMP Securities - Silvan Tuerkcan

Jones Trading - Soumit Roy

Kempen - Sebastiaan van der Schoot

Oddo BHF - Martial Descoutures

RW Baird - Jack Allen

Wells Fargo – Yanan Zhu

Cellectis contact information

Arthur Stril, Chief Financial Officer & Chief Business Officer

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89